TransIT®-LT1 Transfection Reagent

A broad spectrum, low toxicity, DNA transfection reagent

  • Broad Spectrum DNA Delivery - Utilize one transfection reagent and protocol for a variety of cells.
  • Low Cellular Toxicity - Maintain cell density and reduce experimental biases. Learn more >>
  • High Efficiency Delivery - Achieve expression in a large population of cells for experimental success.
  • Deliver Single or Multiple Plasmids - Suitable for applications such as virus production.

Figures and Data

Figure 1: TransIT®-LT1 Reagent Efficiently Transfects Human Induced Pluripotent (iPS) Cells
Figure 2: High Efficiency Transfection of iCell® Cardiomyocytes using TransIT®-LT1
Figure 3: Higher Expression and Lower Toxicity with TransIT®-LT1
Figure 4: Comparable luciferase expression with TransIT®-LT1 and FuGENE® 6 in multiple cell types
Figure 1:TransIT-LT1 Reagent Efficiently Transfects Human Induced Pluripotent (iPS) Cells
Figure 1. Exceptional Transfection Efficiency in Human Induced Pluripotent Stem Cells (iPSCs) via Reverse Transfection with TransIT®-LT1. The TransIT®-LT1 Transfection Reagent was used to reverse transfect 1.3 x 106 iPS cells with a ZsGreen expressing plasmid (Clontech). Reverse transfections were performed in 6-well plates using 12 µl of TransIT®-LT1 Transfection Reagent to deliver 4 µg of DNA (3:1, reagent: DNA). Cells were visualized 48 hours post-transfection and imaged under a 10X objective with an Olympus IX71® Inverted Microscope. Images are (A) phase contrast and (B) green fluorescence. Cells were assayed 48 hours post-transfection on an Accuri® Cytometer. The histogram (C) shows untransfected cells (black line) compared to cells transfected with plasmid using TransIT®-LT1 (green line). See more information on stem cell applications.
Figure 2:High Efficiency Transfection of iCell Cardiomyocytes using TransIT-LT1
Figure 2. High Efficiency Transfection of iCell® Cardiomyocytes using TransIT®-LT1 Transfection Reagent. iCell® Cardiomyocytes were plated at 20,000 cells/well in a 96 well tissue culture plate coated with 0.1% gelatin. After allowing the cells to recover from thaw, cells were transfected with 100 ng/well of pMAXGFP (Lonza) using TransIT®-LT1 Transfection Reagent with a 2:1 reagent-to-DNA ratio according to the manufacturer’s instructions. Fluorescent images were taken 3 days post transfection using a Olympus IX71® inverted microscope. See more information on stem cell applications.

Data courtesy of
CDI logo
Figure 3:Higher Expression and Lower Toxicity with TransIT-LT1
Figure 3. The TransIT®-LT1 Reagent Exhibits Higher Expression and Lower Cellular Toxicity Compared to Other Transfection Reagents. HepG2 cells were transfected with a luciferase expression plasmid using the designated reagents at the manufacturer’s recommended reagent-to-DNA ratio indicated beneath each bar. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression (bar graph) and lactate dehydrogenase (LDH) levels (line graph) were measured at 24 hours post-transfection. LDH levels are reported as % cytotoxicity compared to cells alone and were measured using a commercially available colorimetric assay; all values at or below zero are represented as zero on graph. Experiments were performed as per industry accepted testing protocols. FuGENE® is a registered trademark of Fugent LLC. Lipofectamine® is a trademark of Life Technologies Corporation.
Figure 4:Comparable luciferase expression with TransIT-LT1 and FuGENE 6 in multiple cell types
Figure 4. Comparable Luciferase Expression with the TransIT®-LT1 Reagent and FuGENE® 6 in Multiple Cell Types. The indicated cell lines were transfected in duplicate with 1 µg of a luciferase expression vector per well of a 12-well plate using either 3 µl of the TransIT®-LT1 or FuGENE® 6 Reagents according to industry accepted testing protocols. Cells were harvested 24 hours post-transfection and assayed for luciferase activity. FuGENE® is a registered trademark of Fugent LLC.

Additional Information

NEW! Why compromise your transfection results with toxicity?
NEW! Stem cell applications
TransIT®-LT1 for high-titer virus production